The presence of poor-risk cytogenetic abnormalities, the presence of other mutations in myeloid genes, and the presence of mutations in myelodysplasia-related genes and/or mutations in NRAS/KRAS had no significant effect on the EFS and OS of this group of patients. This evidence concerns the gene KRAS and Myelodysplasia.